Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor

Next Previous
Search
Trial Profile

A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Paclitaxel (Primary) ; Tinengotinib (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Bladder cancer; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; HER2 negative breast cancer; Male breast cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Thyroid cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors TransThera Biosciences

    • Most Recent Events

    • 09 Dec 2024 According to a TransThera Biosciences media release, the company presented Efficacy and Safety Results from this study.
    • 09 Dec 2024 Results(As of September 26, 2024;n=31) published in the TransThera Media Release.
    • 20 Jan 2024 Preliminary Results ( As of 17-Aug-2023, n=6) assessing safety and efficacy of Tinengotinib (TT-00420) in combination with atezolizumab in Chinese patients (pts) with biliary tract carcinoma presented at the 2024 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top